indication

Negative Symptoms in Schizophrenia

Competitive landscape

as of 2026-07-01
Competitive set
2
1 approved · 1 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
16 events
2018
2020
2022
2024
2026
2028
2030
2032
2034
2036
2038
2040
2042
today
focal launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Olanzapine
US-approved 1996 · ZYPREXA Intramuscular
Phase 11 trial
OwnerEli Lilly and Company
Protection2041
drugCompleted
Roluperidone
Pipeline · Phase 1
Phase 11 trial
OwnerMinerva Neurosciences
Protection—

Market size

prevalence as a range, not a number